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Abstract
Background: Pancreatic cancer is the fourth commonest cause of death from cancer in men and
women. Advantages in surgical techniques, radiation therapy techniques, chemotherapeutic
regimes, and different combined-modality approaches have yielded only a modest impact on the
prognosis of patients with pancreatic cancer. Thus there is clearly a need for additional strategies.
One approach involves using the identification of a number of molecular targets that may be
responsible for the resistance of cancer cells to radiation or to other cytotoxic agents. As such,
these molecular determinants may serve as targets for augmentation of the radiotherapy or
chemotherapy response. Of these, the epidermal growth factor receptor (EGFR) has been a
molecular target of considerable interest and investigation, and there has been a tremendous surge
of interest in pursuing targeted therapy of cancers via inhibition of the EGFR.
Methods/design: The PARC study is designed as an open, controlled, prospective, randomized
phase II trial. Patients in study arm A will be treated with chemoradiation using intensity modulated
radiation therapy (IMRT) combined with gemcitabine and simultaneous cetuximab infusions. After
chemoradiation the patients receive gemcitabine infusions weekly over 4 weeks. Patients in study
arm B will be treated with chemoradiation using intensity modulated radiation therapy (IMRT)
combined with gemcitabine and simultaneous cetuximab infusions. After chemoradiation the
patients receive gemcitabine weekly over 4 weeks and cetuximab infusions over 12 weeks. A total
of 66 patients with locally advanced adenocarcinoma of the pancreas will be enrolled. An interim
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analysis for patient safety reasons will be done one year after start of recruitment. Evaluation of the
primary endpoint will be performed two years after the last patient's enrolment.
Discussion: The primary objective of this study is to evaluate the feasibility and the toxicity profile
of trimodal therapy in pancreatic adenocarcinoma with chemoradiation therapy with gemcitabine
and intensity modulated radiation therapy (IMRT) and EGFR-targeted therapy using cetuximab and
to compare between two different methods of cetuximab treatment schedules (concomitant
versus concomitant and sequential cetuximab treatment).
Secondary objectives are to determine the role and the mechanism of cetuximab in patient's 
chemoradiation regimen, the response rate, the potential of this combined modality treatment to 
concert locally advanced lesions to potentially resectable lesions, the time to progression interval 
and the quality of life.
Background
Pancreatic cancer is the fourth commonest cause of death
from cancer in men and women [1,2]. Surgical therapy
currently offers the only potential monomodal cure for
pancreatic adenocarcinoma [3]. However only a few
patients present with tumors that are amenable to resec-
tion, end even after resection of localized cancers, long
term survival is poor. At presentation, only 20% of
patients with pancreatic adenocarcinoma have resectable
cancers, 40% have locally advanced tumors, and 40%
have metastatic disease [5].
However, long-term (5-year) survival rates – even for
patients undergoing "complete" resection – are below
20% [4,5]. Loco-regional recurrence and/or metastatic
disease develop in the majority of patients who undergo
pancreatic resection. Relapse occurs within 9–15 months
after initial presentation and patients have median life
expectancies of only 12–15 months without adjuvant
therapy [4]. The 5-year survival rate of patients with
resected pancreatic adenocarinoma is approximately 10%
[6]. The statistics for the 80 to 90 % of patients who
present with locally advanced and metastatic pancreatic
cancer are even more dismal. Rarely do such patients
achieve a complete response to treatment; median sur-
vival is 5–10 months and 5-year survival is near zero [7].
Both distant and local/regional patterns of recurrence are
common, and this suggests that most patients have occult
metastatic disease or local/regional (or both) at the time
of resection. Postoperative chemoradiationtherapy (CRT)
has been shown to improve survival in patients with
resected pancreatic adenocarcinoma [8-10], although
there is debate over whether radiotherapy is a beneficial
component [5,11]. The problems with the postoperative
adjuvant approach include the fact that at least 25% of
patients do not actually receive adjuvant therapy because
of complications of surgery or patient refusal [10,12]. A
primary advantage of preoperative therapy is therefore the
assurance that CRT is received by all patients in a timely
fashion. Other benefits are the delivers of radiation to
well-oxygenated tissues and the avoidance of radiation to
fixed loops of intestine within the operative field. Another
rationale for neoadjuvant treatment is that occult meta-
static disease is given the opportunity to manifest, thus
allowing patients to avoid the morbidity of resection or
laparotomy. Finally, the potential for preoperative CRT to
convert locally advanced lesions to resectable lesions
could greatly increase the number of patients with pancre-
atic cancer who might be offered a chance of cure. Several
trials could show that dose escalation in radiation therapy
using either EBRT [8] or IORT [13,14] resulted in
improved local control in combination with potentially
curative resection. The efficacy of external beam irradia-
tion (EBRT) in pancreatic cancer is limited by the inability
to deliver adequate doses of irradiation secondary to the
dose tolerance limits of small bowel, spinal cord, stom-
ach, kidney, and liver [15]. Further, the use of combined
modality approaches in pancreatic cancer is associated
with increased gastrointestinal toxicity [16]. Technical
developments like intensity-modulated radiation therapy
(IMRT) have the potential to significantly improve radia-
tion therapy of pancreatic cancers by reducing normal tis-
sue dose, and simultaneously allow escalation of dose to
further enhance locoregional control [17].
To achieve long-term success in treating this disease it is
therefore increasingly important to identify effective neo-
adjuvant/adjuvant multimodality therapies.
Concurrent chemoradiation is the standard of care for
locally advanced non metastatic pancreatic cancers.
Median survival rates vary between different trials
depending on their selection criteria between 7 and 12
month, while 1 year overall survival is between 30% and
45% [18].
Systemic chemotherapy, a mainstay of pancreatic cancer
treatment, essentially has been ineffective until recently
when gemcitabine became available [19]. In a phase IIIBMC Cancer 2005, 5:131 http://www.biomedcentral.com/1471-2407/5/131
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trial comparing gemcitabine versus 5-flurouracil in
advanced pancreatic cancer, patients who received gemcit-
abine showed a modest improvement in response rate, a
marginal survival advantage, and most important, supe-
rior clinical response [20]. Therefore gemcitabine became
the standard treatment of advanced pancreatic cancer.
Despite these results, however median survival duration
in patients with advanced pancreatic cancer continues to
be less than 6 month.
Still, advantages in surgical techniques, radiation therapy
techniques, chemotherapeutic regimes, and different
combined-modality approaches have yielded only a mod-
est impact on the prognosis of patients with pancreatic
cancer. Thus there is clearly a need for additional strate-
gies. One approach involves using the identification of a
number of molecular targets that may be responsible for
the resistance of cancer cells to radiation or to other cyto-
toxic agents. As such, these molecular determinants may
serve as targets for augmentation of the radiotherapy or
chemotherapy response. Of these, the epidermal growth
factor receptor (EGFR) has been a molecular target of con-
siderable interest and investigation, and there has been a
tremendous surge of interest in pursuing targeted therapy
of cancers via inhibition of the EGFR [21,22].
The overexpression of EGFR has been demonstrated in a
number of human tumor types, including head-and-neck
cancers, colon cancer, breast cancer, gliomas, lung cancer
and pancreatic cancer [23,24]. The rationale for investigat-
ing of EGFR inhibitors as radiation sensitizers in cancer
therapy is based on the following observations: (1) posi-
tive correlation between EGFR expression and cellular
resistance to radiation in many cell types [23]; (2) the
degree of radioresistance correlates positively with the
magnitude of EGFR overexpression [25]; (3) cell survival
and repopulation during a course of radiotherapy are
influenced by activation of EGFR/transforming growth
factor alpha that is induced after exposure to radiation
[26]; and (4) inhibition of EGFR signaling-enhanced radi-
ation sensitivity [27,28].
Cetuximab is a monoclonal antibody that specifically
binds to the EGFR, thereby inhibiting downstream signal
transduction pathways [29]. It has been shown in vivo
and in vitro to enhance radiosensitivity, to promote radi-
ation induced apoptosis, to decrease cell proliferation, to
inhibit radiation-induced damage repair, and to inhibit
tumor angiogenesis [23].
Phase I studies have shown that cetuximab has tolerable
toxic effects. Acneiform rash is the most common toxic
effect. Besides skin toxicity cetuximab has the potential to
cause allergic reactions, including anaphylaxis. However,
this has not been shown to be a significant clinical prob-
lem [23].
Phase I and II clinical studies on EGFR antibodies given as
a single agent were performed in patients with advanced
NSCLC, ovarian, head and neck, prostate, and colorectal
cancer. Stable disease with tolerable side effects was seen
in about 20% of the patients [23]. Several phase I-III trials
testing the effect of different EGFR inhibitors combined
with radiotherapy or radiochemotherapy are currently
ongoing. The so far most important trial testing EGFR
inhibition in combination with radiotherapy was a rand-
omized phase III trial testing radiotherapy alone versus
radiotherapy plus cetuximab [30]. 424 patients with loco-
regionally advanced squamous cell carcinoma or head-
and-neck cancers were randomized into curative radio-
therapy plus/minus cetuximab. Cetuximab was applied
once at a dose of 400 mg/m2 in the week prior to radio-
therapy (week1) and weekly during the course of radio-
therapy at a dose of 250 mg/m2  before irradiation.
Locoregional tumor control rates after 1 and 2 years were
69% and 56% for patients treated simultaneously with
cetuximab versus 59% and 48% for patients who received
radiotherapy alone (p = 0.02). Overall survival rates at 2
and 3 years after treatment were 62% and 57% for cetuxi-
mab treated patients and 55% and 44% for patients with
irradiation alone (p = 0.02). Median survival times were
54 months (95%C.I.36;58) and 28 months (21;38),
respectively.
A recently completed phase II trial of cetuximab in combi-
nation with gemcitabine for patients with advanced pan-
creatic cancer showed promising results [31]. In that trial
41 patients received cetuximab with gemcitabine and
were evaluated for efficacy and toxicity. The toxicity pro-
file of this combination was consistent with that of gem-
citabine, except for acneiforme rash induced by
cetuximab. A partial response rate of 12.2% (5 patients)
and stable disease rate of 63.4% was observed in this
study. Medial time to progression and medial survival
duration were 3.8 months and 7.1 months, respectively,
while 1-year survival rates and progression-free survival
rates were 31.7% and 12%, respectively. This 1-year sur-
vival is considerably better than that achieved using gem-
citabine alone as documented in a previous phase III trial
[20]. Recently a phase three study could demonstrate the
benefit of the combination of an EGFR tyrosine kinase
inhibitor in combination with chemotherapy in pancre-
atic cancer [32]. A total of 569 patients with advanced
pancreatic cancer were randomized to receive standard
dose gemcitabine, 1000 mg/m2 iv weekly in 7 out of 8
weeks, than weekly 3 out of four weeks plus either erlotin-
inb 100 mg daily (n = 285) or placebo (n = 284). Com-
bined erlotinib therapy with gemcintabine resulted in a
24% improvment in survival as compared to placebo (p =BMC Cancer 2005, 5:131 http://www.biomedcentral.com/1471-2407/5/131
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0.025) with corresponding 1-year survival rate of 24%
and 17% (erlotinib and placebo arm, respectively).
Regarding the benefits of EGFR-targeted therapy in the
combined modality treatment using either irradiation or
chemotherapy, it is increasingly becoming clear that
EGFR-targeted therapy is an important novel strategy for
the treatment of pancreatic cancers. Since chemoradiation
is the standard of care for locally advanced non metastatic
pancreatic cancer, there has been considerable interest in
gaining increased experience with this therapy in combi-
nation with chemoradiation in an effort to evaluate the
efficacy and the toxicity profile of this regimen.
Methods/design
Trial organization
PARC has been designed by the Trial Center of the Depart-
ment of Radiation Oncology, University of Heidelberg.
The trial is carried out by the Department of Radiation
Oncology together with the German Cancer Research
Center (DKFZ) and Department of Surgery. The trial is an
investigator initiated trial. Trial medication (cetuximab) is
supplied by Merck KGaA, Darmstadt, Germany.
Coordination
The trial is co-ordinated by the Department of Radiation
Oncology in cooperation with the DKFZ and the Depart-
ment of Surgery at the University of Heidelberg. The Dept.
of Radiation Oncology is responsible for overall trial
management, trial registration (International Standard
Randomized Controlled Trial Number [ISRCTN
56652283], http://www.controlled-trials.com), database
management, quality assurance including monitoring,
reporting and for the scientific program of all trial related
meetings).
Investigators
Patients will be recruited by the Department of Radiation
Oncology at the University of Heidelberg. Due to the
multi-modal nature of the trial, all investigators are expe-
rienced oncologists from the fields of radiation oncology,
hematology/oncology, and general surgery at the Univer-
sity of Heidelberg co-operating in this trial.
Adverse events committee
This committee consists of 3 independent physicians
(medical oncologist, radiation oncologist and surgeon)
and decides on the final diagnostic classification of critical
clinical events. For all serious adverse events the docu-
mentation and relevant patient data are verified by the co-
ordinating personnel before submitting the data to the
Adverse Events Committee for diagnostic classification.
Analysis of safety related data is performed with respect to
frequency of:
• Serious Adverse Events and Adverse Events stratified by
organ-system
• Adverse Events stratified by severity
• Adverse Events stratified by causality.
Patient toxicities will be assessed using the NCI Common
Toxicity Criteria (CTC). Toxicity will be evaluated pre-
treatment, weekly during chemoradiation /chemother-
apy, prior to each course of infusional Cetuximab and at
follow-up. Unacceptable toxicity is defined as unpredicta-
ble, or irreversible Grade 4 toxicity. Decisions regarding
weekly chemoradiation treatment, chemotherapy dose-
adjustment, and cetuximab dose-adjustment will be made
using the guidelines below and based on hematological
parameters (ANC and platelets) monitored weekly during
chemoradiation before each dose of cetuximab and
gemcitabine.
Medication supply
All chemotherapeutic agents are prepared and provided
by the pharmacy of the University Hospital Heidelberg.
Cetuximab is provided by Merck KGaA, Darmstadt, and is
stored by the pharmacy of the University Hospital Heidel-
berg. Medication will be prepared for each patient specif-
ically and delivered just prior to administration to the
Department of Radiation Oncology.
On-site monitoring
During recruitment of patients monitoring on site is per-
formed according to good clinical practice (GCP) guide-
lines. The data management will be performed by the Trial
Center of the Department of Radiation Oncology, Univer-
sity of Heidelberg. The medical monitoring will be done
by two independent oncologists not involved in conduct-
ing this trial.
Ethics, informed consent and safety
The final protocol was approved by the ethics committee
of the University of Heidelberg, Medical School (L-283/
2004, http://www.klinikum.uni-heidelberg.de/ Paul-Ehr-
lich-Institute (PEI) registration number 1205/01). This
study complies with the Helsinki Declaration in its recent
German version, the Medical Association's professional
code of conduct, the principles of Good Clinical Practice
(GCP) guidelines and the Federal Data Protection Act. The
trial will also be carried out in keeping with local legal and
regulatory requirements. The medical secrecy and the Fed-
eral Data Protection Act will be followed.
Written informed consent is obtained from each patient
in oral and written form before inclusion in the trial and
the nature, scope, and possible consequences of the trial
have been explained by a physician. The investigator willBMC Cancer 2005, 5:131 http://www.biomedcentral.com/1471-2407/5/131
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not undertake any measures specifically required only for
the clinical trial until valid consent has been obtained.
Patient selection
PARC focuses on hospitalized patients over 18 years of age
treated with pancreatic head resection for pancreatic ade-
nocarcinoma during an 18-months period started in
August 2004. Men and women over eighteen years of age
with locally advanced pancreatic adenocarcinoma will be
screened for participation in the study. A detailed over-
view of all eligibility criteria is given in Table 2.
Study design
The PARC study is designed as an open, controlled, pro-
spective, randomized feasibility phase II trial meant to
evaluate the efficacy and toxicity of chemoradiation in
combination with cetuximab for patients with locally
advanced pancreatic cancer. Compared are chemoradia-
tion with simultaneous cetuximab versus chemoradiation
with simultaneous/sequential cetuximab. The treatment
is offered to a heterogeneous group of people under clin-
ical circumstances, covering a wide age range, for both
sexes and with heterogeneous characteristics / co-morbid-
ities.
One year after inclusion of the first patient an interim
analysis will be performed. The study design will not be
changed prior to agreement of the ethics committee.
Study objectives
The primary objective is to evaluate the feasibility and the
toxicity profile of this regimen and to compare between
two different methods of cetuximab treatment schedules
(concomitant versus concomitant and sequential cetuxi-
mab treatment) in combination with chemoradiation
therapy with gemcitabine and intensity modulated radia-
tion therapy.
Secondary objectives are to determine the role and the
mechanism of cetuximab in patient's chemoradiation reg-
imen, the response rate, the potential of this combined
modality treatment to concert locally advanced lesions to
potentially resectable lesions, the time to progression
interval and the quality of life.
Randomization and standardized treatment scheme
A block-randomization-list is generated via computer sys-
tem (SAS Version 8.2, SAS Institute Inc., Cary, USA). The
sealed randomization list is stored in the investigator file.
Patients are randomized using sealed opaque envelopes
in the independent study center at the Department of
radiation oncology until informed consent is attained and
diagnostic procedures rule out any contra-indication for
participation in this trial.
After randomization and pre-treatment evaluation treat-
ment must begin within 2 weeks.
All patients will receive a combination with radiotherapy,
gemcitabine weekly and cetuximab weekly.
Study arm A
Cetuximab will be given as loading dose 400 mg/m2 over
120 minutes on day 1. On day 8,15,22,29, 36 (5 doses)
cetuximab 250 mg/m2 over 60 minutes will be given
simultaneously with radiation. Non-steroidal anti-inflam-
matory drugs and steroids will be given before cetuximab.
Table 1
Investigation Pretreatment Chemoradiation / 
Chemotherapy weekly
Each Course of 
Infusional Gemcitabine/ 
Cetuximab
follow-up
Clinical examination XXXX
Laboratory tests Xa XXX
Tumor markers Xb XXX
CT Abdomen X Xc
CXR, PA, LAT XX X
Renal function Xd
Pregnancy Testf X
SAE XXX
QOL Survey Xe XXX
a. Includes Electrolytes, BUN, Creatinine, SGOT, Alk Phos, Total Bilirubin, Albumin, Glucose, Calcium, auto-antibodies
b. Includes CEA and CA 19-9
c. A CT scan will be performed 4 weeks after chemoradiation and than every 3 months.
d. Includes CT with i.v. contrast
e. QLQ-C30, QLQ-Pan 26
f. If indicatedBMC Cancer 2005, 5:131 http://www.biomedcentral.com/1471-2407/5/131
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Gemcitabine 300 mg/m2 over 60 minutes will be given on
day 12,19,26,33,40 (5 doses) 2 hours after radiation ther-
apy. Sequential chemotherapy with gemcitabine weekly
1000 mg/m2 over 60 minutes will be continued after fin-
ishing radiotherapy on day 47, 54, 62. The timing of these
courses will be adjusted in patients who have treatment
interruptions.
External beam radiation is to be given concurrently with
chemotherapy and cetuximab with a total dose of 54 Gy
in 25 fractions over 5 weeks. Patients are to be treated
using an integrated intensity modulated radiation therapy
(IMRT) boost concept, which allows the use of different
single doses for the gross target volume (GTV) and the
clinical target volume (CTV) in one fraction. GTV includes
only the gross tumor volume, whereas CTV includes the
primary tumor and the regional lymphnodes including
the hepatoduodenal ligament, origins of the celiac axis
and superior mesenteric artery. The median total dose for
the GTV is to be 54.0 Gy (single dose 2.16 Gy) and for the
CTV 45.0 Gy (single dose 1.8 Gy). The dose constraints for
stomach, duodenum, small intestine, colon are 45 Gy in
the maximum, mean dose for kidneys should be below 10
Gy, only one third of the kidneys should receive more
than 20 Gy. KonRad™ (Siemens Oncology Systems, Con-
corde, USA) will be used for inverse treatment planning.
Treatment will be performed using step-and-shoot IMRT
and stereotactic target point localization with 7 coplanar
fields and 50 to 65 segments. Average treatment time will
be 10 minutes. Patients are to be fixed during therapy by
individual immobilization devices.
Study arm B
Cetuximab will be given as loading dose 400 mg/ m2 over
60 minutes on day 1. On day 8,15,22,29, 36 (5 doses)
cetuximab 250 mg/m2 over 60 minutes will be given
simultaneously with radiation. Non-steroidal anti-inflam-
matory drugs and steroids will be given before cetuximab.
Sequential cetuximab 250 mg/ m2 over 60 minutes will be
given weekly beginning on day 46, over 3 month (12
doses)
Gemcitabine will be given as in study arm A.
External beam radiation will be given as in study arm A.
Restaging using computed tomography will be performed
5 weeks after completion of radiotherapy and at the end
of sequential cetuximab administration.
The treatment protocol is outlined in figure 1.
Investigation schedule and follow-up
All patients (study arm A or B) must have appropriate lab
and radiographic studies (CXR; bone scintigraphy,
abdominal ultrasound, CT abdomen; CBC; platelet count;
BUN; creatinine; bilirubin, CA 19-9, and CEA) conducted
prior to study enrolment to meet eligibility criteria.
During days 1–70 [study arm A] or days 1–130 [study arm
B] patients will be assessed with laboratory evaluation:
complete blood count and blood chemistries weekly. Lab-
oratory parameters in both study arms will be evaluated
Table 2: Eligibility Criteria
Inclusion criteria Exclusion criteria
• Age equal or greater than 18 years
• Primary inoperable locally advanced pancreatic adenocarcinoma
• No evidence of metastatic disease.
• Hb >10.0 g/%, WBC >3,000 cells/mm3, platelets >100,000 cells/mm3.
• Performance status: Karnofsky ≥70.
• No acute infections at the time of therapy initiation.
• Patient must be able to give informed consent
• Patient has given informed consent
• Active infection
• Liver function impairment
• Pregnancy or breastfeeding.
• Metastatic disease
• Other severe systemic disease
• Second malignancy (except carcinoma in situ of the cervix uteri, basal 
cell carcinoma of the skin after adequate oncologic treatment)
• Any other experimental treatment 4 weeks before study inclusion
• Known positive HACA (human antichimeric antibody)
• Known allergy against extrinsical proteins
• Previous antibody therapy
• Allergy against iv contrast agent (for CT-scans)
• Previous chemo- and/or radiation treatment or EGFR-inhibitor therapy 
for pancreatic cancer
• Lack of compliance
• Inability to follow the instructions given by the investigator or the 
telephone interviewer (insufficient command of language, dementia, lack 
of time)
• Lack of informed consentBMC Cancer 2005, 5:131 http://www.biomedcentral.com/1471-2407/5/131
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before each dose of gemcitabine, in study arm B during
cetuximab weekly before cetuximab.
Vital signs (blood pressure and pulse rate) and tempera-
ture are controlled daily during treatment. Patients are
evaluated prior to receiving chemoradiation or
chemotherapy. Patients enrolled in study arm A and B are
evaluated weekly by the radiation oncology team during
treatment. The team will check patients at each visit for
symptoms due to therapy; a physical examination and
complete safety labs should be performed. The quality of
life questionnaire will be filled out during weeks 1, 9 and
17.
During post-chemoradiation, infusional cetuximab
weekly (Study Arm B) patients will be evaluated by a phy-
sician prior to treatment and every 2 to 3 weeks with clin-
ical assessment and laboratory parameters including a
CBC, electrolytes, BUN, and creatinine.
In the post-treatment period patients will be seen every 3
months by the radiation oncology department for the first
2 years, every 4 months for the third year, and every 6
months during the 4th and 5th post-treatment years.
The aggregate clinical, laboratory, and imaging evalua-
tions required per protocol as well as the timing of the
optional quality of life questionnaire are outlined in table
1.
The follow-up will be continued for two years. Follow-up
data of overall survival will be evaluated annually.
Assessment of quality of life
Measurement of quality of life is one of the secondary
objectives of the trial. Overall survival, return to previous
employment as well as persistence of symptoms, the
ability to perform appropriate activities and to care for
oneself are criteria applied in the three questionnaires
used in this study.
EORTC QLQ-C30 is a general measure of qualitiy of life in
cancer patients. It incorporates nine multi-item scales: five
functional scales (physical, role, cognitive, emotional,
and social); three symptom scales (fatigue, pain, and nau-
PARC treatment scheme Figure 1
PARC treatment scheme.
study arm A
1  8   15    22     29    36  43  50   57  day
Cetuximab
gemcitabine
radiation
study arm B
day
Cetuximab
gemcitabine
radiation
1  8   15  22     29    36  43  50   57 
64 to 127 day
Cetuximab
gemcitabine
radiationBMC Cancer 2005, 5:131 http://www.biomedcentral.com/1471-2407/5/131
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sea and vomiting); and a global health and quality-of-life
scale [33]. Specific symptoms (dyspnoea, insomnia, ano-
rexia, constipation, diarrhoea, and financial impact) are
measured as six single items. This instrument has been
used extensively with a variety of cancer patients and was
able to discriminate between individuals with metastatic
and non-metastatic disease, as well as between patients at
different stages of illness. The scale has good internal con-
sistency (alpha > 0.70), and good test re-test reliability
(0.80 to 0.90) [34].
To assess disease-specific symptoms for patients with pan-
creatic cancer the pancreatic specific module (QLQ-
PAN26) [35] that has been designed to use long with the
general measure is used in this study.
Evaluation of the role of cetuximab
An investigation of the effects and mechanism of cetuxi-
mab will be performed. Cetuximab has been shown in
vivo and in vitro to enhance radiosensitivity, to promote
radiation induced apoptosis, to decrease cell prolifera-
tion, to inhibit radiation-induced damage repair, and to
inhibit tumor angiogenesis [23,24,36]. In view of the
encouraging results achieved by using cetuximab in com-
bination with other antineoplastic therapies, studies are
now needed to define the molecular and immunologic
mechanism(s) of this modality [30,31]. If the mechanism
of action of cetuximab is more clearly understood it can
be applied more selectively and its therapeutic index will
be enhanced. Treatment related primary and acquired
chemo- radioresistance presents a significant hindrance
for all current therapy regimes in pancreatic cancer
patients [23,24]. Multiple factors such as genetic instabil-
ity of tumors and high inter- and intratumoral heteroge-
neity contributes to the hardly predictable therapy
resistance [22]. To understand patterns of therapy
response genome expression profiling and detection of
genetic polymorphisms enables to identify key mecha-
nisms in systems biology. Microarray technology will be
used to identify predictors for therapy response or failure.
The objectives are to correlate and potentially predict ther-
apy response to cetuximab in combination with gemcitab-
ine and radiotherapy using tumor genomic fingerprints.
Tissue will be obtained either prior to neoadjuvant ther-
apy by biopsy or during surgery. In order to perform the
genomic approach patients biopsies are correlated and
RNA and DNA isolation will be performed. After expres-
sion profiling the most promising differentially expressed
genes are validated using real-time quantitative polymer-
ase chain reaction. To predict the efficacy of neoadjuvant
trimodal therapy additionally patients blood is collected
before, during, and after neoadjuvant therapy to detect
and correlate well known tumor and angiogenesis marker
(VEGF, bFGF, IL8 etc.) using antibody chips.
Statistical considerations and sample size estimation
The primary endpoint in this study is the feasibility and
safety of the trimodal combination therapy with gemcit-
abine based chemoradiation and cetuximab. Secondary
endpoints are overall survival period, measured from the
date of therapy start. The one-year survival rates after
chemoradiation with gemcitabine is 42 % [20,37]. The
sample size calculation is based on the assumption of an
increase of one-year survival rates up to 67% due to the tri-
ple therapy [30-32].
Assuming an accrual period of 24 months and a follow-up
of 42 months, testing for a difference in hazard (hazard
ratio ≠ 1) on level α = 0.05 and with a power of 80% a
study sample size of 58 patients (29 patients per study
arm) is needed. Taking into consideration the estimate of
approximately 15% of patients which will not complete
the treatment, a total number of 66 patients should be
randomized.
The overall survival between both therapy arms will be
compared using the Chi-square test. The overall survival
will be summarized by Kaplan-Meier estimate and differ-
ences in therapy protocols will be analyzed by univariate
Cox-regression.
Various secondary endpoints will be evaluated in this
study as well, time to progression, measured from date of
therapy start, will be summarized by Kaplan-Meier esti-
mate. Further tumor response after 3, and 6 months and
secondary operability will be calculated
One year after inclusion of the first patient an interim
analysis will be carried out. The main evaluation will be
performed two years after the last patient's enrolment.
There will be explicit stopping rules in place to terminate
the trial early in the unlikely event that an unacceptably
high rate of treatment related deaths (TRD) is observed.
TRD will be monitored using the design of Thall and
Simon [38]. A non-informative Beta prior distribution
(i.e., B (0.015, 0.085) for TRD rate is assumed. The trial
will be stopped if at any point during the trial there is a
greater than 90% probability that the true TRD rate is
greater than 0.05. Each patient will subsequently be eval-
uated and, an independent safety board will be consulted
in making decision.
In view of the poor prognosis of the patient group, there
will be no explicit stopping rules based on the overall
number of toxicities, since even high rates of reversible
toxicities seem acceptable if there is a large survival gain.
Patients can withdraw from study participation at any
time. Patients are taken off the study if unacceptable tox-
icity appears. Unacceptable toxicity is defined as unex-BMC Cancer 2005, 5:131 http://www.biomedcentral.com/1471-2407/5/131
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pected serious side effects or irreversible Grade 4 toxicity.
Patients who withdraw from the study may be treated
with 5-FU and folinic acid or with gemcitabine. The deci-
sion will be based on the individual reasons for withdraw-
ing from the study.
Discussion
About 20–40% of patients present with a locally advanced
pancreatic cancer which is not curable by resection [3,4].
The aim of primary chemoradiation in this situation is to
achieve a local response with the aim prolonged survival
and of preventing local tumor complications. Further
downstaging or downsizing may enable secondary
respectability. Chemoradiation in locally advanced pan-
creatic cancer results in significantly prolonged survival
with 1-year survival about 40% compared to
chemotherapy alone with 1-year survival about 20% [37].
Long-term survival is poor, rarely do such patients achieve
a complete response to treatment; median survival is 5–10
months and 5-year survival is near zero [7].
Advantages in surgical techniques, radiation therapy tech-
niques, chemotherapeutic regimes, and different com-
bined-modality approaches have yielded only a modest
impact on the prognosis of patients with pancreatic cancer
[4]. Thus there is clearly a need for additional strategies.
One approach involves using the identification of a
number of molecular targets that may be responsible for
the resistance of cancer cells to radiation or to other cyto-
toxic agents. As such, these molecular determinants may
serve as targets for augmentation of the radiotherapy or
chemotherapy response. Of these, the epidermal growth
factor receptor (EGFR) has been a molecular target of con-
siderable interest and investigation, and there has been a
tremendous surge of interest in pursuing targeted therapy
of cancers via inhibition of the EGFR [23,36].
Regarding the benefits of EGFR-targeted therapy in the
combined modality treatment using either irradiation or
chemotherapy, it is increasingly becoming clear that
EGFR-targeted therapy is an important novel strategy for
the treatment of pancreatic cancers [30-32]. Since chemo-
radiation is the standard of care for locally advanced non
metastatic pancreatic cancer, there has been considerable
interest in gaining increased experience with this therapy
in combination with chemoradiation in an effort to eval-
uate the efficacy and the toxicity profile of this regimen.
Being a center focusing on pancreatic diseases and espe-
cially malignancies we therefore planned and conduct
such a trial.
The PARC study is an open, randomized controlled trial
investigating the survival of patients with primary non-
metastatic locally advanced pancreatic cancer after trimo-
dal therapy with gemcitabine-based chemoradiation and
EGFR-targeting therapy with the monoclonal antibody
cetuximab. The role and the mechanism of cetuximab in
patient's chemoradiation regimen are evaluated. The tox-
icity, the disease-free interval and the quality of life are
assessed. Different factors are tested for a potential role as
predictive marker.
The results of the PARC trial will definitely advance clini-
cal and scientific knowledge on the treatment of locally
advanced pancreatic adenocarcinoma.
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